Prospective analysis of the use of OnabotulinumtoxinA BOTOX in the treatment of chronic migraine; real-life data in 254 patients from Hull, UKReportar como inadecuado




Prospective analysis of the use of OnabotulinumtoxinA BOTOX in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

The Journal of Headache and Pain

, 15:54

First Online: 01 September 2014Received: 05 June 2014Accepted: 06 August 2014

Abstract

BackgroundChronic migraine affects 2% of the population. It results in substantial disability and reduced quality of life. Medications used for prophylaxis in episodic migraine may also work in chronic migraine. The efficacy and safety of OnabotulinumtoxinA BOTOX in adults with chronic migraine was confirmed in the PREEMPT programme. However, there are few real-life data of its use.

Method254 adults with chronic migraine were injected with OnabotulinumtoxinA BOTOX as per PREEMPT Protocol between July 2010 and May 2013, their headache data were collected using the Hull headache diary and analysed to look for headache, migraine days decrements, crystal clear days increment in the month post treatment, we looked at the 50% responder rate as well.

ResultsOur prospective analysis shows that OnabotulinumtoxinA, significantly, reduced the number of headache and migraine days, and increased the number of headache free days. OnabotulinumtoxinA Botox also improved patients’ quality of life. We believe that these results represent the largest post-marketing cohort of patients treated with OnabotulinumtoxinA in the real-life clinical setting.

ConclusionOnabotulinumtoxinA is a valuable addition to current treatment options in patients with chronic migraine. Our results support findings of PREEMPT study in a large cohort of patients, we believe, is representative of the patients seen in an average tertiary headache centre. While it can be used as a first line prophylaxis its cost may restrict its use to more refractory patients who failed three oral preventive treatments.

Electronic supplementary materialThe online version of this article doi:10.1186-1129-2377-15-54 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Modar Khalil - Hassan W Zafar - Victoria Quarshie - Fayyaz Ahmed

Fuente: https://link.springer.com/







Documentos relacionados